Thanks to the recent advances in deep sequencing, melanomas are now classified at the molecular level depending on the mutational status of their major oncogenic drivers (BRAF, NRAS, and NF1), and are considered as “triple-negative” when no mutations are present in these genes [74]. The gene discussed is NRAS; the disease is melanoma.